Andrew Sochacki
Affiliations: | 2015-2020 | Department of Medicine | Vanderbilt University, Nashville, TN |
Google:
"Andrew Sochacki"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Mack T, Vlasschaert C, von Beck K, et al. (2023) Cost-effective and scalable clonal hematopoiesis assay provides insight into clonal dynamics. Medrxiv : the Preprint Server For Health Sciences |
Sochacki AL, Bejan CA, Zhao S, et al. (2022) Patient-specific comorbidities as prognostic variables for survival in myelofibrosis. Blood Advances |
Moyo TK, Watts JM, Skikne BS, et al. (2019) Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition Blood. 134: 4236-4236 |
Sochacki A, Zhao S, Bejan CA, et al. (2019) JAK2V617F Clonal Hematopoiesis Stratifies By Peripheral Blood Counts. Blood. 134: 1203-1203 |
Bose P, Nazha A, Komrokji RS, et al. (2018) Mutational landscape of myelodysplastic/myeloproliferative neoplasm - unclassifiable (MDS/MPN-U). Blood |
Sochacki A, Bejan CA, Zhao S, et al. (2018) Next Generation Myelofibrosis Risk Analysis in the Electronic Health Record Blood. 132: 3038-3038 |
Sochacki AL, Fischer MA, Savona MR. (2016) Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes. Oncotargets and Therapy. 9: 2273-86 |
Sochacki AL, Fischer MA, Savona MR. (2016) Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes Oncotargets and Therapy. 9: 2273-2286 |
Moyo TK, Sochacki A, Ayers GD, et al. (2016) Preliminary Results from a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis Blood. 128: 1125-1125 |